{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:09:17Z","timestamp":1787069357141,"version":"build-2736575974"},"reference-count":26,"publisher":"Impact Journals, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2022,5,31]]},"DOI":"10.18632\/aging.204101","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:33:21Z","timestamp":1653514401000},"page":"4586-4605","source":"Crossref","is-referenced-by-count":8,"title":["Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers"],"prefix":"10.18632","volume":"14","author":[{"given":"Xiaofan","family":"Su","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi 710061, China"},{"name":"YuceNeo Technology Co., Ltd., Shenzhen 518000, China"},{"name":"YuceBio Technology Co., Ltd., Shenzhen 518020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Jin","sequence":"additional","affiliation":[{"name":"YuceNeo Technology Co., Ltd., Shenzhen 518000, China"},{"name":"YuceBio Technology Co., Ltd., Shenzhen 518020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Wang","sequence":"additional","affiliation":[{"name":"YuceNeo Technology Co., Ltd., Shenzhen 518000, China"},{"name":"YuceBio Technology Co., Ltd., Shenzhen 518020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Lu","sequence":"additional","affiliation":[{"name":"YuceNeo Technology Co., Ltd., Shenzhen 518000, China"},{"name":"YuceBio Technology Co., Ltd., Shenzhen 518020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Gu","sequence":"additional","affiliation":[{"name":"YuceNeo Technology Co., Ltd., Shenzhen 518000, China"},{"name":"YuceBio Technology Co., Ltd., Shenzhen 518020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Gao","sequence":"additional","affiliation":[{"name":"YuceNeo Technology Co., Ltd., Shenzhen 518000, China"},{"name":"YuceBio Technology Co., Ltd., Shenzhen 518020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi 710061, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition.","volume":"37","author":"Jaffee","year":"2017","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.","volume":"35","author":"Murugaesu","year":"2016","journal-title":"Science"},{"key":"3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.","volume":"55","author":"Greenbaum","year":"2017","journal-title":"Nature"},{"key":"4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution.","volume":"56","author":"Wilson","year":"2019","journal-title":"Nature"},{"key":"5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.","volume":"7","author":"Rodgers","year":"2017","journal-title":"Cancer Discov"},{"key":"6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-18-0599","article-title":"Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.","volume":"7","author":"Nagae","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.","volume":"35","author":"Garon","year":"2018","journal-title":"Science"},{"key":"8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.","volume":"1","author":"Braly","year":"2021","journal-title":"Cancer Discov"},{"key":"9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","article-title":"Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.","volume":"18","author":"Bhardwaj","year":"2020","journal-title":"Cell"},{"key":"10","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-19-0585","article-title":"Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.","volume":"2","author":"Zhang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.","volume":"17","author":"Gajewski","year":"2017","journal-title":"Cell"},{"key":"12","doi-asserted-by":"publisher","first-page":"e000367","DOI":"10.1136\/jitc-2019-000367","article-title":"Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.","volume":"8","author":"Han","year":"2020","journal-title":"J Immunother Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.","volume":"1","author":"Zhou","year":"2018","journal-title":"Lancet Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/annonc\/mdx687","article-title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.","volume":"2","author":"Quezada","year":"2018","journal-title":"Ann Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"eaaz3199","DOI":"10.1126\/sciimmunol.aaz3199","article-title":"Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.","volume":"5","author":"Wang","year":"2020","journal-title":"Sci Immunol"},{"key":"16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","article-title":"Evolution of Metastases in Space and Time under Immune Selection.","volume":"17","author":"Humblet","year":"2018","journal-title":"Cell"},{"key":"17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.","volume":"4","author":"Kirilovsky","year":"2016","journal-title":"Immunity"},{"key":"18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity.","volume":"16","author":"Hacohen","year":"2015","journal-title":"Cell"},{"key":"19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.","volume":"1","author":"Savas","year":"2017","journal-title":"Lancet Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform.","volume":"2","author":"Durbin","year":"2009","journal-title":"Bioinformatics"},{"key":"21","unstructured":"Picard. 2013. http:\/\/picard.sourceforge.net\/."},{"key":"22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.","volume":"2","author":"DePristo","year":"2010","journal-title":"Genome Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.","volume":"2","author":"Wilson","year":"2012","journal-title":"Genome Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3.","volume":"6","author":"Ruden","year":"2012","journal-title":"Fly (Austin)"},{"key":"25","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.","volume":"3","author":"Kiezun","year":"2015","journal-title":"Nat Biotechnol"},{"key":"26","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data.","volume":"19","author":"Nielsen","year":"2017","journal-title":"J Immunol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:14:26Z","timestamp":1654686866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,5,31]]}},"alternative-id":["204101","35613927"],"URL":"https:\/\/doi.org\/10.18632\/aging.204101","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}